Related Experiment Video
Updated: Jun 24, 2026

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
The therapeutic potential of targeting B cells and anti-oxLDL antibodies in atherosclerosis
M van Leeuwen1, J Damoiseaux, A Duijvestijn
1Department of Internal Medicine, Section Clinical & Experimental Immunology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands.
While the involvement of T cells in atherosclerosis is nowadays well accepted, little is known about the role of B cells. Obviously, B cells as the source of antibodies, in particular antibodies to oxLDL, have gained a lot of attention in atherosclerosis. In addition, B cells do harbour other functions in adaptive immunity. In this review, we provide an overview of the current knowledge on both the role of B cells and antibodies, i.e., anti-oxLDL antibodies, in atherosclerosis. It appears that B cells and also anti-oxLDL antibodies may comprise pro- and anti-atherogenic effects. Therefore, the establishment of effective therapy, targeting B cells or anti-oxLDL antibodies, warrants further research to unravel these opposite effects.
While the involvement of T cells in atherosclerosis is nowadays well accepted, little is known about the role of B cells. Obviously, B cells as the source of antibodies, in particular antibodies to oxLDL, have gained a lot of attention in atherosclerosis. In addition, B cells do harbour other functions in adaptive immunity. In this review, we provide an overview of the current knowledge on both the role of B cells and antibodies, i.e., anti-oxLDL antibodies, in atherosclerosis. It appears that B cells and also anti-oxLDL antibodies may comprise pro- and anti-atherogenic effects. Therefore, the establishment of effective therapy, targeting B cells or anti-oxLDL antibodies, warrants further research to unravel these opposite effects.
Related Concept Videos
Atherosclerosis III: Management
Pharmacogenomics: Identification of New Drug Targets
Atherosclerosis I: Introduction
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Coronary Artery Disease II: Pathophysiology
Atherosclerosis IV: Nursing Management
